Reply

Affiliations

¹ Departments of Internal Medicine and Pediatrics, Divisions of Allergy and Immunology, University of Tennessee College of Medicine, Memphis, Tenn. Electronic address: phillieberman@hotmail.com.
² Global Product Development, Genentech, Inc, South San Francisco, Calif.
³ Real World Data Science, Genentech, Inc, South San Francisco, Calif.
⁴ Departments of Internal Medicine and Pediatrics, Divisions of Allergy and Immunology, University of Tennessee College of Medicine, Memphis, Tenn.

Comment

Phillip L Lieberman et al. J Allergy Clin Immunol. 2017 May.

. 2017 May;139(5):1718-1719.

doi: 10.1016/j.jaci.2016.12.976. Epub 2017 Mar 3.

¹ Departments of Internal Medicine and Pediatrics, Divisions of Allergy and Immunology, University of Tennessee College of Medicine, Memphis, Tenn. Electronic address: phillieberman@hotmail.com.
² Global Product Development, Genentech, Inc, South San Francisco, Calif.
³ Real World Data Science, Genentech, Inc, South San Francisco, Calif.
⁴ Departments of Internal Medicine and Pediatrics, Divisions of Allergy and Immunology, University of Tennessee College of Medicine, Memphis, Tenn.

No abstract available

Comment on

Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.
Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Lieberman PL, et al. J Allergy Clin Immunol. 2016 Sep;138(3):913-915.e2. doi: 10.1016/j.jaci.2016.03.030. Epub 2016 Apr 26. J Allergy Clin Immunol. 2016. PMID: 27236498 No abstract available.
Omalizumab anaphylaxis occurring outside the recommended observation times.
Kelso JM. Kelso JM. J Allergy Clin Immunol. 2017 May;139(5):1718. doi: 10.1016/j.jaci.2016.12.977. Epub 2017 Mar 6. J Allergy Clin Immunol. 2017. PMID: 28268017 No abstract available.